Literature DB >> 26080908

miRNA-embedded shRNAs for Lineage-specific BCL11A Knockdown and Hemoglobin F Induction.

Swaroopa Guda1,2, Christian Brendel1,2, Raffaele Renella1,2,3, Peng Du1,4, Daniel E Bauer1,2,3, Matthew C Canver2, Jennifer K Grenier5, Andrew W Grimson6, Sophia C Kamran2,7, James Thornton1,4, Helen de Boer1, David E Root5, Michael D Milsom8, Stuart H Orkin1,2,3,7, Richard I Gregory1,4, David A Williams1,2,3.   

Abstract

RNA interference (RNAi) technology using short hairpin RNAs (shRNAs) expressed via RNA polymerase (pol) III promoters has been widely exploited to modulate gene expression in a variety of mammalian cell types. For certain applications, such as lineage-specific knockdown, embedding targeting sequences into pol II-driven microRNA (miRNA) architecture is required. Here, using the potential therapeutic target BCL11A, we demonstrate that pol III-driven shRNAs lead to significantly increased knockdown but also increased cytotoxcity in comparison to pol II-driven miRNA adapted shRNAs (shRNA(miR)) in multiple hematopoietic cell lines. We show that the two expression systems yield mature guide strand sequences that differ by a 4 bp shift. This results in alternate seed sequences and consequently influences the efficacy of target gene knockdown. Incorporating a corresponding 4 bp shift into the guide strand of shRNA(miR)s resulted in improved knockdown efficiency of BCL11A. This was associated with a significant de-repression of the hemoglobin target of BCL11A, human γ-globin or the murine homolog Hbb-y. Our results suggest the requirement for optimization of shRNA sequences upon incorporation into a miRNA backbone. These findings have important implications in future design of shRNA(miR)s for RNAi-based therapy in hemoglobinopathies and other diseases requiring lineage-specific expression of gene silencing sequences.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26080908      PMCID: PMC4817887          DOI: 10.1038/mt.2015.113

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  46 in total

1.  Structural basis for 5'-nucleotide base-specific recognition of guide RNA by human AGO2.

Authors:  Filipp Frank; Nahum Sonenberg; Bhushan Nagar
Journal:  Nature       Date:  2010-05-26       Impact factor: 49.962

2.  The contributions of dsRNA structure to Dicer specificity and efficiency.

Authors:  Annaleen Vermeulen; Linda Behlen; Angela Reynolds; Alexey Wolfson; William S Marshall; Jon Karpilow; Anastasia Khvorova
Journal:  RNA       Date:  2005-04-05       Impact factor: 4.942

3.  Dicer recognizes the 5' end of RNA for efficient and accurate processing.

Authors:  Jong-Eun Park; Inha Heo; Yuan Tian; Dhirendra K Simanshu; Hyeshik Chang; David Jee; Dinshaw J Patel; V Narry Kim
Journal:  Nature       Date:  2011-07-13       Impact factor: 49.962

4.  Regulated and multiple miRNA and siRNA delivery into primary cells by a lentiviral platform.

Authors:  Mario Amendola; Laura Passerini; Ferdinando Pucci; Bernhard Gentner; Rosa Bacchetta; Luigi Naldini
Journal:  Mol Ther       Date:  2009-03-17       Impact factor: 11.454

5.  Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo.

Authors:  Ryan L Boudreau; Inês Martins; Beverly L Davidson
Journal:  Mol Ther       Date:  2008-11-11       Impact factor: 11.454

6.  Lentiviral gene ontology (LeGO) vectors equipped with novel drug-selectable fluorescent proteins: new building blocks for cell marking and multi-gene analysis.

Authors:  K Weber; U Mock; B Petrowitz; U Bartsch; B Fehse
Journal:  Gene Ther       Date:  2009-12-17       Impact factor: 5.250

7.  Proof of principle for transfusion of in vitro-generated red blood cells.

Authors:  Marie-Catherine Giarratana; Hélène Rouard; Agnès Dumont; Laurent Kiger; Innocent Safeukui; Pierre-Yves Le Pennec; Sabine François; Germain Trugnan; Thierry Peyrard; Tiffany Marie; Séverine Jolly; Nicolas Hebert; Christelle Mazurier; Nathalie Mario; Laurence Harmand; Hélène Lapillonne; Jean-Yves Devaux; Luc Douay
Journal:  Blood       Date:  2011-09-01       Impact factor: 22.113

8.  Mammalian microRNAs: experimental evaluation of novel and previously annotated genes.

Authors:  H Rosaria Chiang; Lori W Schoenfeld; J Graham Ruby; Vincent C Auyeung; Noah Spies; Daehyun Baek; Wendy K Johnston; Carsten Russ; Shujun Luo; Joshua E Babiarz; Robert Blelloch; Gary P Schroth; Chad Nusbaum; David P Bartel
Journal:  Genes Dev       Date:  2010-04-22       Impact factor: 11.361

9.  Dendritic cell fate is determined by BCL11A.

Authors:  Gregory C Ippolito; Joseph D Dekker; Yui-Hsi Wang; Bum-Kyu Lee; Arthur L Shaffer; Jian Lin; Jason K Wall; Baeck-Seung Lee; Louis M Staudt; Yong-Jun Liu; Vishwanath R Iyer; Haley O Tucker
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-03       Impact factor: 11.205

10.  Prediction of mammalian microRNA targets.

Authors:  Benjamin P Lewis; I-hung Shih; Matthew W Jones-Rhoades; David P Bartel; Christopher B Burge
Journal:  Cell       Date:  2003-12-26       Impact factor: 41.582

View more
  48 in total

Review 1.  Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease.

Authors:  Megan D Hoban; Stuart H Orkin; Daniel E Bauer
Journal:  Blood       Date:  2016-01-12       Impact factor: 22.113

2.  Forced chromatin looping raises fetal hemoglobin in adult sickle cells to higher levels than pharmacologic inducers.

Authors:  Laura Breda; Irene Motta; Silvia Lourenco; Chiara Gemmo; Wulan Deng; Jeremy W Rupon; Osheiza Y Abdulmalik; Deepa Manwani; Gerd A Blobel; Stefano Rivella
Journal:  Blood       Date:  2016-07-12       Impact factor: 22.113

Review 3.  Customizing the genome as therapy for the β-hemoglobinopathies.

Authors:  Matthew C Canver; Stuart H Orkin
Journal:  Blood       Date:  2016-04-06       Impact factor: 22.113

Review 4.  Manipulation of Developmental Gamma-Globin Gene Expression: an Approach for Healing Hemoglobinopathies.

Authors:  Vigneshwaran Venkatesan; Saranya Srinivasan; Prathibha Babu; Saravanabhavan Thangavel
Journal:  Mol Cell Biol       Date:  2020-12-21       Impact factor: 4.272

5.  Effective and Accurate Gene Silencing by a Recombinant AAV-Compatible MicroRNA Scaffold.

Authors:  Jun Xie; Phillip W L Tai; Alexander Brown; Shoufang Gong; Sha Zhu; Yi Wang; Chengjian Li; Cansu Colpan; Qin Su; Ran He; Hong Ma; Jia Li; Hanqing Ye; Jihye Ko; Phillip D Zamore; Guangping Gao
Journal:  Mol Ther       Date:  2019-11-27       Impact factor: 11.454

6.  Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease.

Authors:  Erica B Esrick; Leslie E Lehmann; Alessandra Biffi; Maureen Achebe; Christian Brendel; Marioara F Ciuculescu; Heather Daley; Brenda MacKinnon; Emily Morris; Amy Federico; Daniela Abriss; Kari Boardman; Radia Khelladi; Kit Shaw; Helene Negre; Olivier Negre; Sarah Nikiforow; Jerome Ritz; Sung-Yun Pai; Wendy B London; Colleen Dansereau; Matthew M Heeney; Myriam Armant; John P Manis; David A Williams
Journal:  N Engl J Med       Date:  2020-12-05       Impact factor: 91.245

Review 7.  Emerging cellular and gene therapies for congenital anemias.

Authors:  Leif S Ludwig; Rajiv K Khajuria; Vijay G Sankaran
Journal:  Am J Med Genet C Semin Med Genet       Date:  2016-10-28       Impact factor: 3.908

Review 8.  The potential of gene therapy approaches for the treatment of hemoglobinopathies: achievements and challenges.

Authors:  Michael A Goodman; Punam Malik
Journal:  Ther Adv Hematol       Date:  2016-06-25

Review 9.  Oxidative Stress in β-Thalassemia.

Authors:  Eitan Fibach; Mutaz Dana
Journal:  Mol Diagn Ther       Date:  2019-04       Impact factor: 4.074

10.  Enhancer Regulation of Transcriptional Bursting Parameters Revealed by Forced Chromatin Looping.

Authors:  Caroline R Bartman; Sarah C Hsu; Chris C-S Hsiung; Arjun Raj; Gerd A Blobel
Journal:  Mol Cell       Date:  2016-04-07       Impact factor: 17.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.